Sells it, part of Other Products“Since 2018, we have launched eight biosimilars, including the 2025 U.S. launches of WEZLANA, a biosimilar to STELARA ® , and BKEMV, a biosimilar to SOLIRIS ® .”
Latest 10-KFY2025Impairment / charge ·
Repatha and TEZSPIRE growth outweighed ENBREL’s price-led decline; Prolia and XGEVA biosimilars threaten faster erosion.
Revenue$36.8BYoY +10.0%
Net income$7.7BYoY +88.5%
Latest 10-QQ3 FY2026 ·
Repatha, UPLIZNA and IMDELLTRA demand more than offsets biosimilar erosion in Prolia and XGEVA.
Revenue$10.4BYoY +8.5%
Net income$3.9BYoY +20.1%
Latest 8-KPositiveEarningsGuidance raised ·
Repatha and IMDELLTRA sales surge as biosimilars hit Prolia and XGEVA; FY2026 revenue outlook rises to $38.9B–$39.7B.
Latest 8-KLeadership change ·
Former Yum! Brands CEO David Gibbs joins the board, bringing direct customer relationship experience to inform future product launches
Latest 8-KCybersecurity incident ·
Third-party cloud data theft deemed material due to file volume and potential sensitivity, including proprietary and patient health information
Latest 8-KShareholder vote ·
Shareholders rejected a requirement for an independent board chairman and elected all director nominees.
Latest 8-KCEO/CFO change ·
Thomas Dittrich returns from Galderma to succeed retiring CFO Peter Griffith, who stays through January 2027 to support the transition.
Latest 8-KDebt financing ·
Issues senior unsecured notes across four tranches, with maturities extending to 2056.
Sells it, part of Product“Product portfolio of off-patent branded and generic sterile injectables, oncology biosimilars and biosimilars for chronic immune and inflammatory diseases – select products include : Biosimilars – Inflectra, Oncology biosimilars such as Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and Sterile Injectables – Sulperazon (outside the U.S. and Canada), Atgam, Fragmin, Solu Medrol, Solu Cortef and Bicillin.”
Latest 10-KFY2025Impairment / charge ·
Paxlovid and Comirnaty declines masked non-COVID growth; the Metsera deal targets obesity as patent losses loom.
Revenue$62.6BYoY −1.6%
Net income$7.8BYoY −3.2%
Latest 10-QQ3 FY2026MixedImpairment / charge ·
Eliquis and Padcev gains counter COVID-19 declines, but pipeline write-downs expose risks in replacing aging franchises.
Revenue$16.6BYoY −0.4%
Net income$3.2BYoY −8.4%
Latest 8-KCEO/CFO change ·
Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.